Bibliography: library/10665-332907

The reference for library/10665-332907 (who-iris) and any references extracted from it. library · All references.

Export these 52 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD

✍ + Add reference (standalone node)

Build a standalone folio-reference/v1 node at references/reference.jsonld from fields or pasted BibTeX / CSL-JSON.



· ✍ Create standalone node on GitHub · Download .jsonld · Download .csl.json ·

52 shown

  1. World Health Organization (2020). Package of care for children and adolescents with advanced HIV disease: stop AIDS: technical brief. World Health Organization.
    10665-332907 · catalogue · link · repository record · ISBN 9789240008045 (electronic version) · source: catalogue/records/10665-332907.dc.json · held: library/10665-332907
    export: BibTeX · RIS · CSL-JSON · DC XML
  2. Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV. 2015;2:e438–44.
    · extracted · source: references/10665-332907.sec-028.1.json
  3. Walker AS, Prendergast AJ, Mugyenyi P, Munderi P, Hakim J, Kekitiinwa A et al. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis. 2012;55:1707–18.
    · extracted · source: references/10665-332907.sec-028.2.json
  4. Lowenthal ED, Bakeera-Kitaka S, Marukutira T, Chapman J, Goldrath K, Ferrand RA. Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges. Lancet Infect Dis. 2014;14:627-639.
    · extracted · source: references/10665-332907.sec-028.3.json
  5. Slogrove AL, Sohn AH. The global epidemiology of adolescents living with HIV: time for more granular data to improve adolescent health outcomes. Curr Opin HIV AIDS. 2018;13:170–8.
    · extracted · source: references/10665-332907.sec-028.4.json
  6. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization; 2017 (https://www.who.int/hiv/pub/guidelines/advanced-HIV-disease/en, accessed 19 June 2020).
    · extracted · link · source: references/10665-332907.sec-028.5.json
  7. Key considerations for differentiated antiretroviral therapy delivery for specific populations: children, adolescents, pregnant and breastfeeding women and key populations. Geneva: World Health Organization; 2017 (https://www.who.int/hiv/pub/arv/hiv-differentiated-care-models-key-populations/en, accessed 19 June 2020).
    · extracted · link · source: references/10665-332907.sec-028.6.json
  8. Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. N Engl J Med. 2017;377:233–45.
    · extracted · source: references/10665-332907.sec-028.7.json
  9. Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015;385:2173–82.
    · extracted · source: references/10665-332907.sec-028.8.json
  10. Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. Geneva: World Health Organization; 2014 (https://www.who.int/tb/publications/childtb_guidelines/en, accessed 19 June 2020).
    · extracted · link · source: references/10665-332907.sec-028.9.json
  11. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach – second edition. Geneva: World Health Organization; 2016 (https://www.who.int/hiv/pub/arv/arv-2016/en, accessed 19 June 2020).
    · extracted · link · source: references/10665-332907.sec-028.10.json
  12. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV: policy update (2019). Geneva: World Health Organization; 2019 (https://www.who.int/tb/publications/2019/LAMPolicyUpdate2019/en, accessed 19 June 2020).
    · extracted · link · source: references/10665-332907.sec-028.11.json
  13. Engel N, Mwaura M. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV: policy update (2019). Report of user perspectives on TB LAM testing: results from qualitative research. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/handle/10665/329513, accessed 19 June 2020).
    · extracted · link · source: references/10665-332907.sec-028.12.json
  14. Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2018 (https://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en, accessed 19 June 2020).
    · extracted · link · source: references/10665-332907.sec-028.13.json
  15. Crook AM, Turkova A, Musiime V, Bwakura-Dangarembizi M, Bakeera-Kitaka S, Nahirya-Ntege P et al. Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy. BMC Med. 2016;14:50.
    · extracted · source: references/10665-332907.sec-028.14.json
  16. Dodd PJ, Prendergast AJ, Beecroft C, Kampmann B, Seddon JA. The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis. Thorax. 2017;72:559–75.
    · extracted · source: references/10665-332907.sec-028.15.json
  17. Abuogi L, Mwachari C, Leslie H, Shade SB, Otieno J, Yienya N et al. Impact of expanded antiretroviral use on incidence and prevalence of tuberculosis in children with HIV in Kenya. Int J Tuberc Lung Dis. 2013;17:1291–7.
    · extracted · source: references/10665-332907.sec-028.16.json
  18. Nicol MP, Allen V, Workman L, Isaacs W, Munro J, Pienaar S et al. Urine lipoarabinomannan testing for diagnosis of pulmonary tuberculosis in children: a prospective study. Lancet Glob Health. 2014;2:e278–84.
    · extracted · source: references/10665-332907.sec-028.17.json
  19. LaCourse SM, Pavlinac PB, Cranmer LM, Njuguna IN, Mugo C, Gatimu J et al. Stool Xpert MTB/RIF and urine lipoarabinomannan (LAM) for diagnosing tuberculosis in hospitalized HIV-infected children. AIDS. 2018;32:69.
    · extracted · source: references/10665-332907.sec-028.18.json
  20. Zar HJ, Workman L, Isaacs W, Munro J, Black F, Eley B et al. Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis. 2012;55:1088–95.
    · extracted · source: references/10665-332907.sec-028.19.json
  21. Bates M, O’Grady J, Maeurer M, Tembo J, Chilukutu L, Chabala C et al. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis. 2013;13:36–42.
    · extracted · source: references/10665-332907.sec-028.20.json
  22. Nicol MP, Workman L, Isaacs W, Munro J, Black F, Eley B et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis. 2011;11:819–24.
    · extracted · source: references/10665-332907.sec-028.21.json
  23. WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. Geneva: World Health Organization; 2017 (https://www.who.int/tb/publications/2017/XpertUltra/en, accessed 19 June 2020).
    · extracted · link · source: references/10665-332907.sec-028.22.json
  24. Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18:76–84.
    · extracted · source: references/10665-332907.sec-028.23.json
  25. Sabi I, Rachow A, Mapamba D, Clowes P, Ntinginya NE, Sasamalo M et al. Xpert MTB/RIF Ultra assay for the diagnosis of pulmonary tuberculosis in children: a multicentre comparative accuracy study. J Infect. 2018;77:321–7.
    · extracted · source: references/10665-332907.sec-028.24.json
  26. Walters E, van der Zalm MM, Palmer M, Bosch C, Demers AM, Draper H et al. Xpert MTB/RIF on stool is useful for the rapid diagnosis of tuberculosis in young children with severe pulmonary disease. Pediatr Infect Dis J. 2017;36:837–43.
    · extracted · source: references/10665-332907.sec-028.25.json
  27. Meiring ST, Quan VC, Cohen C, Dawood H, Karstaedt AS, McCarthy KM et al. A comparison of cases of paediatric-onset and adult-onset cryptococcosis detected through population-based surveillance, 2005– 2007. AIDS. 2012;26:2307–14.
    · extracted · source: references/10665-332907.sec-028.26.json
  28. ARROW Trial Team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013;381:1391–1403.
    · extracted · source: references/10665-332907.sec-028.27.json
  29. Waalewijn H, Mujuru H, Amuge P, Cotton M, Bollen P, Man Chan M et al. Adequate dolutegravir exposure dosed BID with rifampicin in children 6 to <18 years. In: 27th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2020 (https://www.croiconference.org/abstract/adequate-dolutegravir-exposure-dosed-bid-with-rifampicin-in-children-6-to, accessed 19 June 2020).
    · extracted · link · source: references/10665-332907.sec-028.28.json
  30. Revised WHO classification and treatment of pneumonia in children at health facilities: evidence summaries. Geneva: World Health Organization; 2014 (https://www.who.int/maternal_child_adolescent/documents/child-pneumonia-treatment/en, accessed 19 June 2020).
    · extracted · link · source: references/10665-332907.sec-028.29.json
  31. Integrated management of childhood illness for high HIV settings. Geneva: World Health Organization; 2008 (https://apps.who.int/iris/handle/10665/44010, accessed 19 June 2020).
    · extracted · link · source: references/10665-332907.sec-028.30.json
  32. Siberry G, Abzug M, Nachman S. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. Pediatr Infect Dis J. 2013;32:1303–7.
    · extracted · source: references/10665-332907.sec-028.31.json
  33. Newberry L, O’Hare B, Kennedy N, Selman A, Omar S, Dawson P et al. Early use of corticosteroids in infants with a clinical diagnosis of Pneumocystis jiroveci pneumonia in Malawi: a double-blind, randomised clinical trial. Paediatr Int Child Health. 2017;37:121–8.
    · extracted · source: references/10665-332907.sec-028.32.json
  34. McNally LM, Jeena PM, Gajee K, Thula SA, Sturm AW, Cassol S et al. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. Lancet. 2007;369:1440–51.
    · extracted · source: references/10665-332907.sec-028.33.json
  35. Goussard P, Kling S, Gie R, Nel ED, Heyns L, Rossouw GJ et al. CMV pneumonia in HIV-infected ventilated infants. Pediatr Pulmonol. 2010;45:650–5.
    · extracted · source: references/10665-332907.sec-028.34.json
  36. le Roux DM, Cotton MF, le Roux SM, Whitelaw A, Lombard CJ, Zar HJ. Bacteremia in human immunodeficiency virus-infected children in Cape Town, South Africa. Pediatr Infect Dis J. 2011;30:904–6.
    · extracted · source: references/10665-332907.sec-028.35.json
  37. Musiime V, Cook A, Bakeera-Kitaka S, Vhembo T, Lutakome J, Keishanyu R et al. Bacteremia, causative agents and antimicrobial susceptibility among HIV-1–infected children on antiretroviral therapy in Uganda and Zimbabwe. Pediatr Infect Dis J. 2013;32:856–62.
    · extracted · source: references/10665-332907.sec-028.36.json
  38. Archary M, Adler H, La Russa P, Mahabeer P, Bobat RA. Bacterial infections in HIV-infected children admitted with severe acute malnutrition in Durban, South Africa. Paediatr Int Child Health. 2017;37:6–13.
    · extracted · source: references/10665-332907.sec-028.37.json
  39. Tabu C, Breiman RF, Ochieng B, Aura B, Cosmas L, Audi A et al. Differing burden and epidemiology of non-Typhi Salmonella bacteremia in rural and urban Kenya, 2006–2009. PLOS One. 2012;7.
    · extracted · source: references/10665-332907.sec-028.38.json
  40. Archary M, Sartorius B, La Russa P, Sibaya T, Healy M, Bobat RA. Effect of the timing of antiretroviral treatment initiation on outcomes in children living with human immunodeficiency virus admitted with severe acute malnutrition. J Pediatr Infect Dis Soc. 2020 [online ahead of print]. doi: 10.1093/jpids/piaa054.
    · extracted · doi:10.1093/jpids/piaa054 · source: references/10665-332907.sec-028.39.json
  41. Njuguna IN, Cranmer LM, Otieno VO, Aura B, Cosmas L, Audi A et al. Urgent versus post-stabilisation antiretroviral treatment in hospitalised HIV-infected children in Kenya (PUSH): a randomised controlled trial. Lancet HIV. 2018;5:e12–22.
    · extracted · source: references/10665-332907.sec-028.40.json
  42. Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007;334:136.
    · extracted · source: references/10665-332907.sec-028.41.json
  43. Global tuberculosis report 2019. Geneva: World Health Organization; 2019 (https://www.who.int/tb/publications/global_report/en, accessed 19 June 2020).
    · extracted · link · source: references/10665-332907.sec-028.42.json
  44. Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med. 2011;365:21–31.
    · extracted · source: references/10665-332907.sec-028.43.json
  45. Ruffini DD, Madhi SA. The high burden of Pneumocystis carinii pneumonia in African HIV-1-infected children hospitalized for severe pneumonia. AIDS. 2002;16:105–12.
    · extracted · source: references/10665-332907.sec-028.44.json
  46. Chintu C, Mudenda V, Lucas S, Nunn A, Lishimpi K, Maswahu D et al. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet. 2002;360:985–90.
    · extracted · source: references/10665-332907.sec-028.45.json
  47. Chintu C, Bhat G, Walker A, Mulenga V, Sinyinza F, Lishimpi K et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet. 2004;364:1865–71.
    · extracted · source: references/10665-332907.sec-028.46.json
  48. Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo K et al. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med. 2014;370:41– 53.
    · extracted · source: references/10665-332907.sec-028.47.json
  49. Keenan JD, Bailey RL, West SK, Arzika AM, Hart J, Weaver J et al. Azithromycin to reduce childhood mortality in sub-Saharan Africa. N Engl J Med. 2018;378:1583–92.
    · extracted · source: references/10665-332907.sec-028.48.json
  50. Rabie H, Violari A, Duong T, Madhi SA, Josipovic D, Innes S et al. Early antiretroviral treatment reduces risk of bacille Calmette-Guerin immune reconstitution adenitis. Int J Tuberc Lung Dis. 2011;15:1194–200.
    · extracted · source: references/10665-332907.sec-028.49.json
  51. Sohn AH, Kerr SJ, Hansudewechakul R, Gatechompol S, Chokephaibulkit K, Dang HLD et al. Risk factors for human papillomavirus infection and abnormal cervical cytology among perinatally human immunodeficiency virus-infected and uninfected Asian youth. Clin Infect Dis. 2018;67:606–13.
    · extracted · source: references/10665-332907.sec-028.50.json
  52. Mugo NR, Eckert L, Magaret AS, Cheng A, Mwaniki L, Ngure K et al. Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: month 7 and 12 post vaccine immunogenicity and correlation with immune status. Vaccine. 2018;36:7025–32. For more information, contact: World Health Organization Department of HIV/AIDS 20, avenue Appia 1211 Geneva 27 Switzerland E-mail: hiv-aids@who.int www.who.int/hiv
    · extracted · link · source: references/10665-332907.sec-028.51.json